Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emgality in episodic migraine
NCT02163993Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2014
- Primary completion
- Aug 2015
- Countries
- 1
01
Overview
A Phase 2 trial of galcanezumab in migraine, sponsored by Eli Lilly and Company. Started Jul 2014; status: completed.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02163993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02163993.